Furiex Pharmaceuticals to Present at Cowen & Company 33rd Annual Healthcare
Cowen Group Healthcare Conference 2013
MORRISVILLE, N.C. -- February 26, 2013
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration
company, announced today that June Almenoff, M.D., Ph.D., president and chief
medical officer of Furiex, is scheduled to present at the Cowen 33^rd Annual
Healthcare Conference in Boston, MA on Monday, March 4, 2013 at 2:10 p.m. ET.
Dr. Almenoff will provide a corporate overview and discuss Furiex’s
A live webcast of Furiex’s presentation may be accessed through the
Presentations & Events link in the Investors section of the company’s website
at www.furiex.com. A replay of the webcast will be available on Furiex’s
website for 90 days following the conference.
Furiex Pharmaceuticals is a drug development collaboration company that uses
innovative clinical development design to accelerate and increase value of
drug development programs by advancing them through the drug discovery and
development process in a cost-efficient manner. Our drug development programs
are designed and driven by a core team with extensive drug development
experience. The company collaborates with pharmaceutical and biotechnology
companies and has a diversified product portfolio and pipeline with multiple
therapeutic candidates, including one Phase III-ready asset, two compounds in
Phase III development, one of which is with a partner, three products on the
market and a fourth approved in the United States but not yet launched. The
company's mission is to develop innovative medicines faster and at a lower
cost, thereby improving profitability and accelerating time to market while
providing life-improving therapies for patients. For more information, visit
Furiex Pharmaceuticals, Inc.
Sailash Patel, 919-456-7814
Press spacebar to pause and continue. Press esc to stop.